Carol Wrenn - Phibro Animal Independent Director

PAHC Stock  USD 16.76  0.41  2.51%   

Director

Ms. Carol A. Wrenn is Independent Director of the company since July 2010. Ms. Wrenn also serves as a member of the Audit Committee and the Compensation Committee. She is the founder and owner of Whitewater Advisors LLC, which provides consulting services to small businesses and Aurora Borealis LLC, which operates online retail businesses. She was the founder and owner of Sky River Helicopters, LLC, a company that provides helicopter charters, tours, commercial services and lessons, from January 2010 until September 2015. She previously served as an Executive Vice President and the President of the Animal Health Division at Alpharma Inc., a human and animal pharmaceutical company, from November 2001 to June 2009. From April 2007 to April 2009, Ms. Wrenn also held the position of Chairman of the Animal Health Institute, an industry organization advocating for animal health issues, including efficient and effective FDA, USDA and EPA regulatory and approval processes. From January 2002 to June 2009, she was an active member of the Board of Directors of the International Federation of Animal Health. Prior to joining Alpharma, Ms. Wrenn held various executive positions at Honeywell International Inc. from 1984 to 2001. She served as Business Director of Honeywells Refrigerants, Fluorine Products Division from 2000 to 2001 and was the Commercial Director and Managing Director of Honeywells European Fluorochemical operations based in Haasrode, Belgium from 1997 to 2000. Ms. Wrenn also held a number of positions in sales, marketing, business development and finance during her tenure with AlliedSignal. Beginning in January 2013, Ms. Wrenn has served as a director of Heska Corporationrationration. She holds a Bachelors Degree from Union College, an MBA from Lehigh University and a DBA from California Southern University. Ms since 2010.
Age 57
Tenure 14 years
Professional MarksMBA
Address Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712
Phone201 329 7300
Webhttps://www.pahc.com
Wrenn also held a number of positions in sales, marketing, business development and finance during her tenure with AlliedSignal. Beginning in January 2013, Ms. Wrenn has served as a director of Heska Corporationrationrationration. She holds a Bachelor’s Degree from Union College and an MBA from Lehigh University.

Phibro Animal Management Efficiency

The company has return on total asset (ROA) of 0.0372 % which means that it generated a profit of $0.0372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0549 %, meaning that it created $0.0549 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Tangible Assets are forecasted to decline to 0.02. At present, Phibro Animal's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 76.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 15.6 M.
The company currently holds 509.97 M in liabilities with Debt to Equity (D/E) ratio of 1.79, which is about average as compared to similar companies. Phibro Animal Health has a current ratio of 2.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Phibro Animal until it has trouble settling it off, either with new capital or with free cash flow. So, Phibro Animal's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Phibro Animal Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Phibro to invest in growth at high rates of return. When we think about Phibro Animal's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Patricia AllenDeciphera Pharmaceuticals LLC
56
James BristolDeciphera Pharmaceuticals LLC
71
Steven RatoffEagle Pharmaceuticals
81
Richard EdlinEagle Pharmaceuticals
57
Douglas BraunsteinEagle Pharmaceuticals
57
Sander FlaumEagle Pharmaceuticals
81
Michael RossDeciphera Pharmaceuticals LLC
68
Dennis WalshDeciphera Pharmaceuticals LLC
50
Liam RatcliffeDeciphera Pharmaceuticals LLC
53
Edward BenzDeciphera Pharmaceuticals LLC
71
Michael GravesEagle Pharmaceuticals
61
Robert GlenningEagle Pharmaceuticals
57
Alain SchreiberEagle Pharmaceuticals
58
Edward KayEagle Pharmaceuticals
N/A
David PernockEagle Pharmaceuticals
63
John MartinDeciphera Pharmaceuticals LLC
57
Susan KelleyDeciphera Pharmaceuticals LLC
63
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for food and companion animals. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey. Phibro Anl operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1860 people. Phibro Animal Health (PAHC) is traded on NASDAQ Exchange in USA. It is located in Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712 and employs 1,920 people. Phibro Animal is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Phibro Animal Health Leadership Team

Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ramon Fuenmayor, President Region
Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations
Damian Finio, Chief Officer
Daniel Welch, Sr. VP of HR
Jean Filippi, Pres Region
Richard Johnson, Interim Officer
Gerald Carlson, Director
Mary Malanoski, Independent Director
Rob Aukerman, President Region
Jack Bendheim, Chairman of the Board and Presidentident, CEO
Anthony Andolino, Vice President - Finance, Treasurer
Michael Giambalvo, President Group
Sam Gejdenson, Independent Director
Lisa Escudero, Senior Vice President-Human Resources
Dean Warras, President - Animal Health & Nutrition, North America
Larry Miller, Chief Officer
Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary
Glenn David, Chief Officer
Daniel Bendheim, Executive Vice President Director, Corporate Strategy
David Storbeck, Vice President - Finance, Treasurer
Judith Weinstein, General VP
George Gunn, Independent Director
Thomas Corcoran, Independent Director
Carol Wrenn, Independent Director
Samson Li, President Region

Phibro Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Phibro Animal in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Phibro Animal's short interest history, or implied volatility extrapolated from Phibro Animal options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Phibro Animal Health using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Phibro Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phibro Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phibro Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phibro Animal Health Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the Phibro Animal Health information on this page should be used as a complementary analysis to other Phibro Animal's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Phibro Stock analysis

When running Phibro Animal's price analysis, check to measure Phibro Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phibro Animal is operating at the current time. Most of Phibro Animal's value examination focuses on studying past and present price action to predict the probability of Phibro Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phibro Animal's price. Additionally, you may evaluate how the addition of Phibro Animal to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is Phibro Animal's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phibro Animal. If investors know Phibro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phibro Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.83)
Dividend Share
0.48
Earnings Share
0.37
Revenue Per Share
24.245
Quarterly Revenue Growth
0.022
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.